menu
    • menu
    [{"orgOrder":0,"company":"University of North Carolina","sponsor":"Colgate Palmolive","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Chlorhexidine","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of North Carolina \/ Colgate Palmolive","highestDevelopmentStatusID":"8","companyTruncated":"University of North Carolina \/ Colgate Palmolive"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Colgate Palmolive","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Chlorhexidine","moa":"Cell membrane","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of North Carolina \/ Colgate Palmolive","highestDevelopmentStatusID":"11","companyTruncated":"University of North Carolina \/ Colgate Palmolive"},{"orgOrder":0,"company":"Colgate Palmolive","sponsor":"German Cancer Research Center","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Chlorhexidine","moa":"Cell membrane","graph1":"Dental and Oral Health","graph2":"Phase III","graph3":"Colgate Palmolive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Paste","sponsorNew":"Colgate Palmolive \/ German Cancer Research Center","highestDevelopmentStatusID":"10","companyTruncated":"Colgate Palmolive \/ German Cancer Research Center"},{"orgOrder":0,"company":"Cukurova University","sponsor":"BioGaia Pharma | SUNSTAR AMERICAS INC","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"TURKEY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Chlorhexidine","moa":"Cell membrane","graph1":"Dental and Oral Health","graph2":"Undisclosed","graph3":"Cukurova University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cukurova University \/ BioGaia Pharma | SUNSTAR AMERICAS INC","highestDevelopmentStatusID":"1","companyTruncated":"Cukurova University \/ BioGaia Pharma | SUNSTAR AMERICAS INC"},{"orgOrder":0,"company":"University of Texas Health Science Center at Tyler","sponsor":"Irrimax Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Chlorhexidine","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"University of Texas Health Science Center at Tyler","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"University of Texas Health Science Center at Tyler \/ Irrimax Corporation","highestDevelopmentStatusID":"11","companyTruncated":"University of Texas Health Science Center at Tyler \/ Irrimax Corporation"}]

    Find Clinical Drug Pipeline Developments & Deals for Dentisept [veterinary] (TN)

    Menu

    Dentisept [veterinary] (TN)

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            University of Texas Health Science Center at Tyler

                            Country arrow
                            FNCE
                            Not Confirmed

                            University of Texas Health Science Center at Tyler

                            Country arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chlorhexidine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Irrimax Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Irrisept in Emergency General Surgery Patients

                            Details : Chlorhexidine is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Surgical Wound Infection.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 03, 2025

                            Lead Product(s) : Chlorhexidine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Irrimax Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Colgate Palmolive

                            India arrow
                            FNCE
                            Not Confirmed

                            Colgate Palmolive

                            India arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chlorhexidine

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase III

                            Sponsor : German Cancer Research Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Effect of a Toothpaste Containing 0.3% Chlorhexidine in Subjects With Established Dental Pla...

                            Details : Chlorhexidine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Gingivitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 13, 2024

                            Lead Product(s) : Chlorhexidine

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase III

                            Sponsor : German Cancer Research Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cukurova University

                            Country arrow
                            FNCE
                            Not Confirmed

                            Cukurova University

                            Country arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chlorhexidine

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Undisclosed

                            Sponsor : BioGaia Pharma | SUNSTAR AMERICAS INC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Use of Chlorhexidine and a Probiotic Lozenge in the Nonsurgical Therapy of Periodontitis

                            Details : Chlorhexidine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Periodontitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 21, 2022

                            Lead Product(s) : Chlorhexidine

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Undisclosed

                            Sponsor : BioGaia Pharma | SUNSTAR AMERICAS INC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            University of North Carolina

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            University of North Carolina

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chlorhexidine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Colgate Palmolive

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Baseline Oral Health Study: UnCoVer the Connections to General Health

                            Details : Chlorhexidine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cardiovascular Diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 08, 2021

                            Lead Product(s) : Chlorhexidine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Colgate Palmolive

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            University of North Carolina

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            University of North Carolina

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chlorhexidine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Colgate Palmolive

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Antiviral Efficacy and Acceptability of Mouth Rinses for Inactivation of COVID-19

                            Details : Periogard is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 10, 2021

                            Lead Product(s) : Chlorhexidine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Colgate Palmolive

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth